ArticleResearch square2026
Structural and genetic analysis of neutralizing antibodies reveals mechanisms of GII.4 norovirus antigenic evolution.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Noroviruses are a leading cause of acute gastroenteritis worldwide, yet no licensed vaccines or antivirals are available. A major barrier to broadly protective vaccine development is the extensive genetic and antigenic diversity of these viruses, leading to immune escape. However, the structural mechanisms underlying this immune escape remain incompletely defined. Here, we analyze a panel of monoclonal antibodies generated against a pandemic GII.4 variant to define the molecular determinants of neutralizing immunity. Guided by immunogenetic features and cross-reactivity patterns spanning four decades of viral evolution, we resolved the atomic structures of two neutralizing antibodies targeting the principal immunodominant antigenic sites, A and G. We show that the spatial positioning of antigenic site G shapes neutralizing responses and that coordinated substitutions within these epitopes drove the rapid antigenic transitions observed between 2004 and 2012.Together, these findings establish a structural framework for GII.4 antigenic evolution and inform rational vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.